These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 38550598)
1. Immune checkpoint inhibitors combined with concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma. Huang JQ; Liang HW; Liu Y; Chen L; Pei S; Yu BB; Pan XB Front Immunol; 2024; 15():1355198. PubMed ID: 38550598 [TBL] [Abstract][Full Text] [Related]
2. Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study. Lian HM; Wu JL; Liufu WJ; Yu TT; Niu SQ; Bao Y; Peng F Cancer Immunol Immunother; 2024 Feb; 73(3):55. PubMed ID: 38366287 [TBL] [Abstract][Full Text] [Related]
3. Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers. Huang C; Zhu Y; Li Q; Zhang W; Liu H; Zhang W; Hu Y; Yuan Y; Liu M Cancer Med; 2019 Jan; 8(1):28-39. PubMed ID: 30600600 [TBL] [Abstract][Full Text] [Related]
4. Feasibility and efficiency of concurrent chemoradiotherapy with capecitabine and cisplatin versus radiotherapy alone for elderly patients with locally advanced esophageal squamous cell carcinoma: Experience of two centers. Chen F; Luo H; Xing L; Liang N; Xie J; Zhang J Thorac Cancer; 2018 Jan; 9(1):59-65. PubMed ID: 29024498 [TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant vs definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma patients. Chen CY; Li CC; Chien CR World J Surg Oncol; 2018 Jul; 16(1):141. PubMed ID: 30007409 [TBL] [Abstract][Full Text] [Related]
6. Comparison of concurrent chemoradiotherapy with radiotherapy alone for locally advanced esophageal squamous cell cancer in elderly patients: A randomized, multicenter, phase II clinical trial. Liu Y; Zheng Z; Li M; Zhang Y; Zhao F; Gong H; Lin H; Huang W; Chen X; Xu Z; Li X; Liu W; Cui Y; Zheng A; Li B Int J Cancer; 2022 Aug; 151(4):607-615. PubMed ID: 35419831 [TBL] [Abstract][Full Text] [Related]
7. The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma. Hu L; Kong Z; Meng Q; Wang J; Zhou M; Yu J; Jiang X Med Sci Monit; 2020 Nov; 26():e927221. PubMed ID: 33243967 [TBL] [Abstract][Full Text] [Related]
8. Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma. Zhou XL; Yu CH; Wang WW; Ji FZ; Xiong YZ; Zhu WG; Tong YS Radiat Oncol; 2021 May; 16(1):94. PubMed ID: 34039375 [TBL] [Abstract][Full Text] [Related]
9. Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Park S; Oh D; Choi YL; Chi SA; Kim K; Ahn MJ; Sun JM Cancer; 2022 Jun; 128(11):2148-2158. PubMed ID: 35319779 [TBL] [Abstract][Full Text] [Related]
10. Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: A propensity score matching and landmark analyses. Shi Z; Zhu X; Ke S; Qiu H; Cai G; Zhangcai Y; Chen Y Radiother Oncol; 2021 Nov; 164():236-244. PubMed ID: 34627936 [TBL] [Abstract][Full Text] [Related]
11. Sintilimab as maintenance treatment for local/regional recurrent esophageal squamous carcinoma after concurrent chemoradiotherapy: a single-arm Ib/II phase study. Liu C; Sun H; Huang W; Wang Z; Fu C; Han D; Zhao Q; Wu X; Li B Front Immunol; 2023; 14():1193394. PubMed ID: 37325650 [TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of safety profile of high-dose concurrent chemoradiotherapy for patients with oesophageal squamous cell carcinoma. Ren X; Wang L; Han C; Ren L Radiother Oncol; 2018 Nov; 129(2):293-299. PubMed ID: 30270099 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of chemoradiotherapy plus immune checkpoint inhibitors for the treatment of locally advanced cervical cancer: a systematic review and meta-analysis. Zhao Z; Ruan J; Fang M; Liu J; Liao G Front Immunol; 2024; 15():1459693. PubMed ID: 39351236 [TBL] [Abstract][Full Text] [Related]
14. Comparative Clinical Efficacy of 'Concurrent Chemoradiotherapy (CCRT) and Anlotinib' Than CCRT in Patients with Locally Advanced ESCC. Wang G; Beeraka NM; Xiao W; Zhang Y; Xue N; Chen G; Liu J; Liu Y Technol Cancer Res Treat; 2022; 21():15330338221080939. PubMed ID: 35235470 [No Abstract] [Full Text] [Related]
15. Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score-matched analysis. Li C; Tan L; Liu X; Wang X; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Wang X; Bi N; Deng L; Wang W; Zhang T; Ni W; Chang X; Han W; Gao L; Wang S; Xiao Z Thorac Cancer; 2021 Jun; 12(12):1831-1840. PubMed ID: 33949784 [TBL] [Abstract][Full Text] [Related]
16. Is there a benefit in receiving concurrent chemoradiotherapy for elderly patients with inoperable thoracic esophageal squamous cell carcinoma? Zhang P; Xi M; Zhao L; Shen JX; Li QQ; He LR; Liu SL; Liu MZ PLoS One; 2014; 9(8):e105270. PubMed ID: 25133495 [TBL] [Abstract][Full Text] [Related]
17. Lymphopenia in Esophageal Squamous Cell Carcinoma: Relationship to Malnutrition, Various Disease Parameters, and Response to Concurrent Chemoradiotherapy. Zhou XL; Zhu WG; Zhu ZJ; Wang WW; Deng X; Tao WJ; Ji FZ; Tong YS Oncologist; 2019 Aug; 24(8):e677-e686. PubMed ID: 31040254 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the Clinical Outcomes of Esophagectomy and Concurrent Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma. Lee MH; Park MI; Lee JW; Jung K; Kim JH; Kim SE; Moon W; Park SJ Korean J Gastroenterol; 2024 Mar; 83(3):102-110. PubMed ID: 38522853 [TBL] [Abstract][Full Text] [Related]
19. Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching. Jing SW; Zhai C; Zhang W; He M; Liu QY; Yao JF; Wang R; Tian ZQ; Wang J; Liu JF Front Immunol; 2022; 13():970534. PubMed ID: 36275724 [TBL] [Abstract][Full Text] [Related]
20. With or without consolidation chemotherapy using cisplatin/5-FU after concurrent chemoradiotherapy in stage II-III squamous cell carcinoma of the esophagus: A propensity score-matched analysis. Chen Y; Guo L; Cheng X; Wang J; Zhang Y; Wang Y; Ke S; Shi W Radiother Oncol; 2018 Oct; 129(1):154-160. PubMed ID: 29122362 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]